Insomnia
291 results
244 - 291
Opioid antagonists with minimal sedation for opioid withdrawal- Oral budesonide for induction of remission in ulcerative colitis
- Risperidone versus olanzapine for schizophrenia
- Adjuvant therapy with antidepressants for the management of inflammatory bowel disease: Cochrane systematic review
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
- Budesonide for maintenance of remission in Crohn's disease
Seasonal affective disorder (SAD) - Pharmacological treatment of depression
- Oestrogen and combined oestrogen/progestogen replacement therapy for hot flushes
- Short‐course oral steroids as an adjunct therapy for chronic rhinosinusitis
- Ginkgo biloba for tinnitus
- Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome
- Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
- Pharmacotherapy for sleep bruxism
- Green tea (Camellia sinensis) for the prevention of cancer
- Second‐generation antidepressants for preventing seasonal affective disorder in adults
- Acupuncture for schizophrenia
- Honey for acute cough in children
- Fluvoxamine for the treatment of COVID‐19
- Ganoderma lucidum (Reishi mushroom) for cancer treatment
- Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain
- Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder
- Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications: Cochrane systematic review
- Antidepressants for people with epilepsy and depression
- Systemic and topical antibiotics for chronic rhinosinusitis
- Sound therapy (using amplification devices and/or sound generators) for tinnitus
- Placebo interventions for all clinical conditions: Cochrane systematic review
- Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety disorders in adults
- Antidepressants for the treatment of depression in people with cancer
- Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
- Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Antidepressants plus benzodiazepines for adults with major depression
- Pharmacotherapies for sleep disturbances in dementia
- Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies: Cochrane systematic review
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)
- Lifestyle education in type 2 diabetes
- Neuromodulators for pain management in rheumatoid arthritis
- Varenicline and bupropion and suicidal behaviour
- Functional bowel disorders and the irritable bowel syndrome (IBS)
- Use of medication during pregnancy